About ARS Pharmaceuticals, Inc.
https://ars-pharma.comARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
CEO
Richard E. Lowenthal MSMSEL
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 112
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.86M
Value:$128.05M
ORBIMED ADVISORS LLC
Shares:8.29M
Value:$97.72M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:7.5M
Value:$88.47M
Summary
Showing Top 3 of 202
About ARS Pharmaceuticals, Inc.
https://ars-pharma.comARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $32.5M ▲ | $77.5M ▲ | $-51.15M ▼ | -157.38% ▲ | $-0.52 ▼ | $-48.8M ▼ |
| Q2-2025 | $15.72M ▲ | $58.35M ▲ | $-44.88M ▼ | -285.57% ▲ | $-0.46 ▼ | $-44.6M ▼ |
| Q1-2025 | $7.97M ▼ | $41.1M ▲ | $-33.94M ▼ | -425.69% ▼ | $-0.35 ▼ | $-36.9M ▼ |
| Q4-2024 | $86.58M ▲ | $35.49M ▲ | $49.93M ▲ | 57.67% ▲ | $0.51 ▲ | $47.23M ▲ |
| Q3-2024 | $2.07M | $23.7M | $-19.13M | -924.95% | $-0.2 | $-21.73M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $288.21M ▲ | $372.8M ▲ | $225.15M ▲ | $147.66M ▼ |
| Q2-2025 | $240.13M ▼ | $313.47M ▼ | $121.15M ▲ | $192.32M ▼ |
| Q1-2025 | $275.73M ▼ | $327.32M ▼ | $98.34M ▲ | $228.97M ▼ |
| Q4-2024 | $314.02M ▲ | $351.15M ▲ | $94.36M ▲ | $256.8M ▲ |
| Q3-2024 | $204.62M | $217.6M | $16.62M | $200.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-51.15M ▼ | $-47.05M ▼ | $-44.98M ▼ | $100.05M ▲ | $8.02M ▼ | $-47.24M ▼ |
| Q2-2025 | $-44.88M ▼ | $-39.59M ▲ | $48.57M ▲ | $2.7M ▲ | $11.68M ▲ | $-39.64M ▲ |
| Q1-2025 | $-33.94M ▼ | $-40.74M ▼ | $29.06M ▲ | $725K ▼ | $-10.95M ▼ | $-40.83M ▼ |
| Q4-2024 | $49.93M ▲ | $42M ▲ | $-101.76M ▼ | $70.92M ▲ | $11.16M ▲ | $41.7M ▲ |
| Q3-2024 | $-19.13M | $-14.47M | $16.82M | $680K | $3.03M | $-14.61M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 |
|---|---|---|---|
 Product | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
CEO
Richard E. Lowenthal MSMSEL
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 112
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.86M
Value:$128.05M
ORBIMED ADVISORS LLC
Shares:8.29M
Value:$97.72M
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:7.5M
Value:$88.47M
Summary
Showing Top 3 of 202